Article info
Student essay
Moral ambivalence towards the Cancer Drugs Fund
- Correspondence to Mr Ilias Ektor Epanomeritakis; iee21{at}cam.ac.uk
Citation
Moral ambivalence towards the Cancer Drugs Fund
Publication history
- Received March 4, 2019
- Revised June 22, 2019
- Accepted June 28, 2019
- First published July 16, 2019.
Online issue publication
September 09, 2019
Article Versions
- Previous version (9 September 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
- Potential for epistemic injustice in evidence-based healthcare policy and guidance
- Justice and procedure: how does “accountability for reasonableness” result in fair limit-setting decisions?
- The ethical canary: narrow reflective equilibrium as a source of moral justification in healthcare priority-setting
- Value assessment frameworks: who is valuing the care in healthcare?
- NICE rejects trastuzumab emtansine for use on NHS
- NICE and the Cancer Drugs Fund—2020 vision?
- Cancer drugs: high price, uncertain value
- Most drugs paid for by £1.27bn Cancer Drugs Fund had no “meaningful benefit”
- How should we assess the clinical and cost effectiveness of histology independent cancer drugs?